China: How much cooling is Beijing likely to tolerate?

The US-China trade war looks set to escalate. According to press reports, US President Trump will most likely impose a 25% tariff on imports from China worth US$ 200 bn (while repeating his threat to tax about all of imports from China).

Authors: Christoph Siepmann

Highlights:

  • The US-China trade war looks set to escalate. US President Trump will most likely impose a 25% tariff on another US$ 200 bn of imports from China. China will use its available space for retaliatory measures worth US$ 60 bn.
  • The trade conflict comes on top of China’s regulatory tightening of the shadow banking sector, which has already led to a negative credit impulse but affected the real economy so far only by slowing infrastructure investment.
  • Given this double risk, China is likely to recalibrate its economic policy:
  • We expect monetary policy to further ease liquidity in order to offset the negative impact from regulatory tightening on credit growth, but not to give up on its de-risking program altogether.
  • We see fiscal policy in charge to mitigate the negative impact from the trade conflict in order to protect the 6.5% 2018 growth target. For 2019, we stick to our 6.2%-6.3% growth forecast, assuming China’s reform agenda to be held up.

Read the full publication below.

CHINA: HOW MUCH COOLING IS BEIJING LIKELY TO TOLERATE?

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.